Search results for "VACCINE"

showing 10 items of 801 documents

RSV disease in infants and young children: Can we see a brighter future?

2022

Respiratory syncytial virus (RSV) is a highly contagious seasonal virus and the leading cause of Lower Respiratory Tract Infections (LRTI), including pneumonia and bronchiolitis in children. RSV-related LRTI cause approximately 3 million hospitalizations and 120,000 deaths annually among children <5 years of age. The majority of the burden of RSV occurs in previously healthy infants. Only a monoclonal antibody (mAb) has been approved against RSV infections in a restricted group, leaving an urgent unmet need for a large number of children potentially benefiting from preventive measures. Approaches under development include maternal vaccines to protect newborns, extended half-life monoclon…

respiratory syncytial virusImmunologyRSV vaccinesRespiratory Syncytial Virus InfectionsCommunicable DiseasesRSV preventionRSV all infantsImmunology and AllergyHumansChildmonoclonal antibodieRespiratory Tract InfectionsPharmacologyRSV all infantInfant NewbornRSVInfantAntibodies MonoclonalRSV paediatric burdenHospitalizationLRTIRSV epidemiologyChild PreschoolRespiratory Syncytial Virus HumanBronchiolitismonoclonal antibodiesLRTI; RSV; RSV all infants; RSV epidemiology; RSV paediatric burden; RSV prevention; RSV vaccines; monoclonal antibodies; respiratory syncytial virusRSV prevention: RSV vaccines.Human vaccinesimmunotherapeutics
researchProduct

Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in h…

2021

A quadrivalent high-dose inactivated influenza vaccine (IIV4-HD) is licensed for adults ≥65 y of age based on immunogenicity and efficacy studies. However, IIV4-HD has not been evaluated in adults aged 60–64 y. This study compared immunogenicity and safety of IIV4-HD with a standard-dose quadrivalent influenza vaccine (IIV4-SD) in adults aged ≥60 y. This Phase III, randomized, modified double-blind, active-controlled study enrolled 1,528 participants aged ≥60 y, randomized 1:1 to a single injection of IIV4-HD or IIV4-SD. Hemagglutination inhibition (HAI) geometric mean titers (GMTs) were measured at baseline and D 28 and seroconversion assessed. Safety was described for 180 d after vaccinat…

safetyAdultIMPACTInfluenza vaccineImmunologyimmunogenicityAntibodies ViralQuadrivalent Influenza Vaccineolder adultImmunogenicity VaccineDouble-Blind MethodInfluenza HumanMedicine and Health SciencesImmunology and AllergyMedicineHumansVaccines Combinedolder adultsPharmacologybusiness.industryImmunogenicityADULTSHemagglutination Inhibition TestsEFFICACYVirologyinfluenza vaccinationHigh-dose influenza vaccineVaccines InactivatedInfluenza VaccinesPhase III trialbusinessHuman vaccinesimmunotherapeutics
researchProduct

Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial

2020

Funding: Transgène; International audience; Treatment of chronic hepatitis B (CHB) typically requires life-long administration of drugs. Cohort and pre-clinical studies have established the link between a functional T-cell-mounted immunity and resolution of infection. TG1050 is an adenovirus 5-based vaccine that expresses HBV polymerase and domains of core and surface antigen and has shown immunogenicity and antiviral effects in mice. We performed a phase 1 clinical trial to assess safety and explore immunogenicity and early efficacy of TG1050 in CHB patients. This randomized, double blind, placebo-controlled study included two sequential phases: one single dose cohort (SD, n = 12) and one …

safetyHBsAg030231 tropical medicineImmunologyPlacebo-controlled studyPhases of clinical researchSciences du Vivant [q-bio]/Médecine humaine et pathologieimmunogenicityPlaceboAntiviral AgentsAdenoviridae03 medical and health sciencesMice0302 clinical medicineHepatitis B ChronicImmunogenicity VaccinevaccineImmunology and AllergyMedicineAnimalsHumans030212 general & internal medicineAdverse effectPharmacologyVaccinesHepatitis B Surface Antigens[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologybusiness.industryELISPOTImmunogenicitychronicityimmuno-therapyHepatitis Bmedicine.diseaseHepatitis B3. Good healthImmunologybusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyResearch Paper
researchProduct

Combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Hemophilus influenzae type b vaccine; Infanrix™ hexa: T…

2014

Infant vaccination using 2-dose priming at 3 and 5 mo of age with a booster at 11–12 mo of age was pioneered in Italy. The 3-5-11 schedule is now used in a growing number of European countries. Infanrix™ hexa (DTPa-HBV-IPV/Hib, GlaxoSmithKline Vaccines) was first licensed for use in 2000 and has been the only pediatric hexavalent vaccine available since 2005. We reviewed available clinical trial data describing the immunogenicity of DTPa-HBV-IPV/Hib when administered at 3, 5, and 11 mo of age, and conducted an analysis of safety using global and Italian post-marketing surveillance data. In Italy, DTPa-HBV-IPV/Hib has a demonstrated safety record extending over a decade of use, it has been a…

safetybooster vaccination; combination vaccines; hexavalent vaccine; immunogenicity; Italy; primary vaccination; safety; Clinical Trials as Topic; Diphtheria-Tetanus-Pertussis Vaccine; Haemophilus Vaccines; Hepatitis B Vaccines; Humans; Italy; Poliovirus Vaccine Inactivated; Product Surveillance Postmarketing; Vaccination; Vaccines Combined; Medicine (all)Settore MED/42 - Igiene Generale e ApplicataImmunologySocio-culturaleReviewimmunogenicitySettore MED/42 - Igiene Generale E Applicatamedicine.disease_causeprimary vaccinationProduct Surveillance PostmarketingmedicineImmunology and AllergyHumansHepatitis B VaccinesVaccines CombinedDiphtheria-Tetanus-Pertussis VaccineHaemophilus VaccinesPharmacologycombination vaccinesbooster vaccination; combination vaccines; hexavalent vaccine; immunogenicity; Italy; primary vaccination; safety; Medicine (all)Clinical Trials as TopicVaccinescombination vaccineTetanusbusiness.industryCombinedImmunogenicityPoliovirusDiphtheriaMedicine (all)VaccinationInactivatedHepatitis Bmedicine.diseaseVirologyProduct SurveillancePostmarketingClinical trialVaccinationPoliovirus Vaccinebooster vaccinationPoliovirus Vaccine InactivatedInfanrix hexaItalyhexavalent vaccine; primary vaccination; booster vaccination; Italy; combination vaccines; immunogenicity; safetybusinesshexavalent vaccine
researchProduct

Dexamethasone premedication suppresses vaccine-induced immune responses against cancer

2020

ABSTRACT Glucocorticosteroids (GCS) have an established role in oncology and are administered to cancer patients in routine clinical care and in drug development trials as co-medication. Given their strong immune-suppressive activity, GCS may interfere with immune-oncology drugs. We are developing a therapeutic cancer vaccine, which is based on a liposomal formulation of tumor-antigen encoding RNA (RNA-LPX) and induces a strong T-cell response both in mice as well as in humans. In this study, we investigated in vivo in mice and in human PBMCs the effect of the commonly used long-acting GCS Dexamethasone (Dexa) on the efficacy of this vaccine format, with a particular focus on antigen-specif…

t-cell primingPremedicationmedicine.medical_treatmentImmunologyPriming (immunology)dexamethasoneglucocorticosteroidsProinflammatory cytokineMice03 medical and health sciences0302 clinical medicineImmune systemAntigenCancer immunotherapyNeoplasmsAnimalsHumansImmunology and AllergyMedicineRC254-282Original ResearchMice Inbred BALB Ccancer immunotherapybusiness.industryrna vaccineImmunityNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC581-607Mice Inbred C57BLCytokineOncology030220 oncology & carcinogenesisImmunologyt-cell vaccineFemaleCancer vaccineImmunologic diseases. AllergybusinessT-cell vaccineResearch Article030215 immunologyOncoImmunology
researchProduct

Algunos aspectos de la asimilación de la teoría del contagio animado en la España del siglo XIX

1999

La aceptación de la teoría del contagio animado en España durante el siglo XIX llevó a la superación de la teoría miasmática como explicación del origen de las enfermedades infecciosas y a la integración de las explicaciones parasitológicas de la sarna, la helmintiasis y la tiña, con la vacunación antivariólica y los datos aportados por la nueva microbiología. Ello permitió la resolución de problemas como la infección quirúrgica y la fabricación de sueros y vacunas. El último cuarto de siglo vio la consolidación definitiva de esta teoría, con la aparición de una legislación y unas instituciones específicas dedicadas a la microbiología, así como las primeras exposiciones sistemáticas de la n…

teoria del contagi animatanimated contagian theoryfabricación de vacunasmicrobiología19th centurymicrobiologia:CIENCIAS DE LA VIDA::Inmunología ::Vacunas [UNESCO]teoría del contagio animadoinfectious diseasesmiasmatic theory:CIENCIAS DE LA VIDA::Microbiología [UNESCO]fabricació de vacunessegle XIXUNESCO::CIENCIAS MÉDICAS ::Medicina interna::Enfermedades infecciosasVacunació:HISTORIA::Historia por especialidades::Historia de la medicina [UNESCO]UNESCO::CIENCIAS DE LA VIDA::Microbiologíateoria miasmàticaUNESCO::CIENCIAS DE LA VIDA::Inmunología ::VacunasmicrobiologyVacunaciónmalalties infecciosesvaccinationsiglo XIXvaccines productionUNESCO::HISTORIA::Historia por especialidades::Historia de la medicinateoría miasmáticaenfermedades infecciosas:CIENCIAS MÉDICAS ::Medicina interna::Enfermedades infecciosas [UNESCO]
researchProduct

The Role of Existential Concerns in the Individual’s Decisions regarding COVID-19 Vaccine Uptake: A Survey among Non-Vaccinated Italian Adults during…

2022

Recent studies have suggested that health constructs embraced by the Terror Management Theory (TMT) and the Basic Psychological Needs Theory (BPNT) may drive individuals’ COVID-19 health-related decisions. This study examines the relationships between existential concerns (ECs; within the TMT), basic psychological needs (BPNs; within the BPNT) and COVID-19 vaccine hesitancy (VH), as well as the mediating role of negative attitudes toward COVID-19 vaccines. A cross-sectional survey was carried out from April to May 2021 on a sample of two hundred and eighty-seven adults (Mage = 36.04 ± 12.07; 59.9% females). Participants provided information regarding existential concerns, basic psychologica…

vaccine hesitancy; existential concerns; basic psychological needs; attitudes; COVID-19; Pfizer-BioNTech vaccine; AstraZeneca vaccinePharmacologyattitudesInfectious Diseasesexistential concernsDrug DiscoveryImmunologybasic psychological needsCOVID-19vaccine hesitancyPharmacology (medical)AstraZeneca vaccinePfizer-BioNTech vaccineVaccines
researchProduct

Obbligo vaccinale e discrezionalità legislativa a proposito delle ordinanze CGARS nn.38 e 351 del 2022

2022

The paper deals with two ordinances of the CGARS on the subject of vaccination obligation, retracing the events that first led to the preliminary order no. 38/2022 and then to the reasoned order for referral to the constitutional court.

vaccine obbligation legislative discretionSettore IUS/08 - Diritto Costituzionale
researchProduct

Note a margine dell'ordinanza del Consiglio di giustizia amministrativa della regione siciliana del 17 gennaio 2022 n. 38 in tema di obbligo vaccinal…

2022

This is a comment on the ordinance of the CGA of the Sicilian region on the subject of vaccination obligation in relation to certain categories of subjects.

vaccine obligation covid-19Settore IUS/08 - Diritto Costituzionale
researchProduct

Obbligo vaccinale e limiti: una recente decisione del Consiglio di Giustizia Amministrativa della Regione Siciliana

2022

This brief paper analyses the obligation of Covid-19 vaccine provided by Italian legislation for workers of the National Health Service. In the order n. 38 of 2022, the Council of Sicilian Administrative Justice decided to verify the possibility to impose mandatory Covid-19 vaccine in relation to Art. 32nd of the Italian Constitution, which provides freedom of self-determination in health choices. Moreover, this principle has to be connected to the general principle of solidarity , enshrined in the Art. 2nd of the Italian Constitution.

vaccino solidarietàSettore IUS/08 - Diritto Costituzionalevaccine solidarity
researchProduct